Management of Membranous Nephropathy after MENTOR

Claire Trivin-Avillach, Laurence H Beck

Clinical Journal of the American Society of Nephrology: CJASN 2019 November 18

No abstract text is available yet for this article.

Read this article (multiple options)

OPEN IN READ APP

PUBMED • http://www.ncbi.nlm.nih.gov/pubmed/31740571

Find additional links »

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. Barbara Seitz-Polski, Christine Payré, Damien Ambrosetti, Laetitia Albano, Elisabeth Cassuto-Viguier, Marine Berguignat, Ahmed Jeribi, Marie-Christine Thouret, Ghislaine Bernard, Sylvia Benzaken, Gérard Lambeau, Vincent L M Esnault Nephrology, Dialysis, Transplantation 2014, 29 (12): 2334-42

Primary Membranous Nephropathy. William G Couser Clinical Journal of the American Society of Nephrology: CJASN 2017 June 7, 12 (6): 983-997

[Membranous nephropathy: Pathophysiology and natural history]. Barbara Seitz-Polski, Gérard Lambeau, Vincent Esnault Néphrologie & Thérapeutique 2017, 13 Suppl 1: S75-S81

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Jorge Enrique Rojas-Rivera, Sol Carriazo, Alberto Ortiz Clinical Kidney Journal 2019, 12 (5): 629-638

M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Elion Hoxha, Sigrid Harendza, Hans Pinnschmidt, Ulf Panzer, Rolf A K Stahl Clinical Journal of the American Society of Nephrology: CJASN 2014 November 7, 9 (11): 1883-90

Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. Barbara Seitz-Polski, Hanna Debiec, Alexandra Rousseau, Karine Dahan, Christelle Zaghrini, Christine Payré, Vincent L M Esnault, Gérard Lambeau, Pierre Ronco Journal of the American Society of Nephrology: JASN 2018, 29 (2): 401-408

Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Yizhi Chen, Arrigo Schieppati, Xiangmei Chen, Guangyan Cai, Javier Zamora, Giovanni A Giuliano, Norbert Braun, Annalisa Perna Cochrane Database of Systematic Reviews 2014 October 16, (10): CD004293

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Fernando C Fervenza, Pietro A Canetta, Sean J Barbour, Richard A Lafayette, Brad H Rovin, Nabeel Aslam, Michelle A Hladunewich, Maria V Irazabal, Sanjeev Sethi, Debbie S Gipson, Heather N Reich, Paul Brenchley, Matthias Kretzler, Jai Radhakrishnan, Lee A Hebert, Patrick E Gipson, Leslie F Thomas, Ellen T McCarthy, Gerald B Appel, J Ashley Jefferson, Alfonso Eirin, John C Lieske, Marie C Hogan, Eddie L Greene, John J Dillon, Nelson Leung, John R Sedor, Dana V Rizk, Samuel S Blumenthal, Lada B Lasic, Luis A Juncos, Dollie F Green, James Simon, Amy N Sussman, David Philibert, Daniel C Cattran Nephron 2015, 130 (3): 159-68

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Piero Ruggenenti, Hanna Debiec, Barbara Ruggiero, Antonietta Chianca, Timothee Pellé, Flavio Gaspari, Flavio Suardi, Elena Gagliardini, Silvia Orisio, Ariela Benigni, Pierre Ronco, Giuseppe Remuzzi Journal of the American Society of Nephrology: JASN 2015, 26 (10): 2545-58

[Membranous nephropathy: New insights in therapeutic approach]. Karine Dahan Néphrologie & Thérapeutique 2017, 13 Suppl 1: S83-S87

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Management of Membranous Nephropathy after MENTOR

Discussion

Related Papers

Want full text access to this paper?

Read

Search Tips